0000000000139414

AUTHOR

Francesc Artigas

0000-0002-5880-5720

showing 6 related works from this author

Diez años de investigación traslacional colaborativa en enfermedades mentales: el CIBERSAM

2019

Psychiatry and Mental healthbusiness.industryMedicinebusinessHumanitiesRevista de Psiquiatría y Salud Mental
researchProduct

Phencyclidine-induced disruption of oscillatory activity in prefrontal cortex: Effects of antipsychotic drugs and receptor ligands

2016

The non-competitive NMDA receptor (NMDA-R) antagonist phencyclidine (PCP) markedly disrupts thalamocortical activity, increasing excitatory neuron discharge and reducing low frequency oscillations (LFO, <4Hz) that temporarily group neuronal discharge. These actions are mainly driven by PCP interaction with NMDA-R in GABAergic neurons of the thalamic reticular nucleus and likely underlie PCP psychotomimetic activity. Here we report that classical (haloperidol, chlorpromazine, perphenazine) and atypical (clozapine, olanzapine, quetiapine, risperidone, ziprasidone, aripripazole) antipsychotic drugs - but not the antidepressant citalopram - countered PCP-evoked fall of LFO in the medial prefron…

Male0301 basic medicineOscillationsmedicine.drug_classDopamine AgentsAtypical antipsychoticPhencyclidineKainate receptorPharmacologyNeurotransmissionPrefrontal cortex03 medical and health scienceschemistry.chemical_compoundSerotonin Agents0302 clinical medicineHistamine AgentsmedicineAnimalsPharmacology (medical)NMDA receptor antagonistsAntipsychotic drugsRats WistarChlorpromazineEvoked PotentialsPhencyclidineBiological PsychiatryPharmacologyRacloprideAnalysis of VarianceDose-Response Relationship DrugFourier AnalysisChemistryElectroencephalographyPsychotomimeticRatsPsychiatry and Mental health030104 developmental biologyNeurologynervous systemSchizophreniaNBQXNeurology (clinical)Excitatory Amino Acid AntagonistsNeuroscience030217 neurology & neurosurgeryAntipsychotic Agentsmedicine.drug
researchProduct

Phencyclidine inhibits the activity of thalamic reticular gamma-aminobutyric acidergic neurons in rat brain.

2014

Póster presentado en el IX Simposi de Neurobiologia Experimental, celebrado los días 22 y 23 de octubre de 2014 en Barcelona y organizado por la Societat Catalana de Biologia del Institut d'Estudis Catalans

MaleAction PotentialsPhencyclidinePrefrontal CortexLocal field potentialGABA AntagonistsThalamusthalamocortical networksNeural PathwaysmedicinePremovement neuronal activityAnimalsNMDA receptor antagonistsAntipsychotic drugsGABAergic NeuronsRats WistarPrefrontal cortexReceptorPhencyclidineClozapineBiological PsychiatryClozapineAnalysis of VarianceChemistryRatsschizophreniaElectrophysiologyParvalbuminspsychotic symptomsExcitatory postsynaptic potentialHallucinogensNeurosciencemedicine.drugBiological psychiatry
researchProduct

Subchronic vortioxetine treatment -but not escitalopram- enhances pyramidal neuron activity in the rat prefrontal cortex.

2017

Abstract Vortioxetine (VOR) is a multimodal antidepressant drug. VOR is a 5-HT 3 -R, 5-HT 7 -R and 5-HT 1D -R antagonist, 5-HT 1B -R partial agonist, 5-HT 1A -R agonist, and serotonin transporter (SERT) inhibitor. VOR shows pro-cognitive activity in animal models and beneficial effects on cognitive dysfunction in major depressive patients. Here we compared the effects of 14-day treatments with VOR and escitalopram (ESC, selective serotonin reuptake inhibitor) on neuronal activity in the medial prefrontal cortex (mPFC). Ten groups of rats (5 standard, 5 depleted of 5-HT with p -chlorophenylalanine -pCPA-, used as model of cognitive impairment) were fed with control food or with two doses of …

0301 basic medicineAgonistMalegenetic structuresmedicine.drug_classSerotonin reuptake inhibitorAction PotentialsPrefrontal CortexPharmacologyCitalopramSulfidesPartial agonistPiperazines03 medical and health sciencesCellular and Molecular Neuroscience0302 clinical medicinemedicinePremovement neuronal activityAnimalsRats WistarSerotonin transporterPharmacologyVortioxetinebiologyPyramidal CellsAntagonistAntidepressive AgentsRats030104 developmental biologybiology.proteinAntidepressantVortioxetinesense organsPsychologyNeuroscience030217 neurology & neurosurgerySelective Serotonin Reuptake InhibitorsNeuropharmacology
researchProduct

Selective α-synuclein knockdown in monoamine neurons by intranasal oligonucleotide delivery: potential therapy for parkinson’s disease

2018

Progressive neuronal death in brainstem nuclei and widespread accumulation of α-synuclein are neuropathological hallmarks of Parkinson’s disease (PD). Reduction of α-synuclein levels is therefore a potential therapy for PD. However, because α-synuclein is essential for neuronal development and function, α-synuclein elimination would dramatically impact brain function. We previously developed conjugated small interfering RNA (siRNA) sequences that selectively target serotonin (5-HT) or norepinephrine (NE) neurons after intranasal administration. Here, we used this strategy to conjugate inhibitory oligonucleotides, siRNA and antisense oligonucleotide (ASO), with the triple monoamine reuptake …

0301 basic medicineanimal diseasesDopamineOligonucleotidesGene ExpressionPharmacologySynaptic TransmissionPrefrontal cortexMiceDA neurotransmission0302 clinical medicineDrug DiscoveryMonoaminergicNeural PathwaysRNA Small InterferingCells Cultured5-HT neurotransmissionChemistryGene Transfer TechniquesParkinson DiseaseVentral tegmental areaSubstantia Nigramedicine.anatomical_structureCaudate putamenGene Knockdown Techniquesalpha-SynucleinMolecular MedicineRNA InterferenceOriginal ArticleMonoamine reuptake inhibitormedicine.drugSignal TransductionSerotoninSubstantia nigraASO03 medical and health sciencesProsencephalonα-synucleinDopamineIntranasal administrationGeneticsmedicineAnimalsHumansMolecular BiologyAdministration IntranasalPharmacologyPars compactaDopaminergic NeuronsGenetic TherapyCorpus Striatumnervous system diseases030104 developmental biologyMonoamine neurotransmitterGene Expression Regulationnervous systemsiRNAParkinson’s diseaseLocus coeruleus030217 neurology & neurosurgery
researchProduct

Association between CCK-AR gene and schizophrenia with auditory hallucinations

2007

[Objective]: Previous studies on a possible association between CCK-AR polymorphisms and schizophrenia have been controversial. The aim of the present study was to assess a potential association between schizophrenic patients with auditory hallucinations and polymorphisms of the CCK-AR gene.

medicine.medical_specialtyGenotypeHallucinationsSingle-nucleotide polymorphismAuditory hallucinationsRegulatory Sequences Nucleic Aciddigestive systemPolymorphism Single NucleotideGene FrequencyReference ValuesInternal medicineGenotypeGene expressionGeneticsmedicineHumansSNPCCK-AR geneAllelePsychiatryGeneBiological PsychiatryGenetics (clinical)DNA Primersbusiness.industrydigestive oral and skin physiologyHaplotypeDNAmedicine.diseaseReceptor Cholecystokinin APsychiatry and Mental healthEndocrinologySchizophreniaSchizophreniaSchizophrenic Psychologybusinesshormones hormone substitutes and hormone antagonistsPsychiatric Genetics
researchProduct